Developer docs
API playgroundTry for free, no card

Search company profiles

EDAP TMS

Full company profile

uuid00026ab

Namestring
EDAP TMS
Legal namestring
EDAP TMS S.A.
Websiteurl
edap-tms.com
Company typeenum
Public
Founded yearint
1979
Descriptiontext

EDAP TMS S.A., now operating as FocalTherics (NASDAQ: FOCL, formerly EDAP), is a French medical device company that has pivoted from a diversified therapeutic ultrasound portfolio to a pure-play robotic focal therapy business. The company develops and commercializes the Focal One platform — a robotic High Intensity Focused Ultrasound (HIFU) system for non-invasive prostate tissue ablation. Focal One combines a five-degrees-of-freedom robotic positioning system with submillimetric precision, a Dynamic Focusing Probe that fuses real-time ultrasound imaging with HIFU energy delivery, and the proprietary HIFUsion open-platform software that performs elastic fusion of MRI and 3D biopsy maps for treatment planning. The platform is sold as the Focal One and Focal One i systems, with the Focal One Eye variant launched in the U.S. in August 2025. Headquartered in Lyon, France with a U.S. commercial office in Austin, Texas, the company holds regulatory clearances in the U.S., Europe, Canada, Korea, Russia, Brazil, and other markets, supported by 154 peer-reviewed publications and major clinical studies including HIFI, FARP, and HIFI-2.

The company generates revenue through direct enterprise capital sales of Focal One systems to hospital urology departments and specialty urology clinics, supplemented by an operating lease option and a recurring procedure-driven disposables stream. The installed base reached 87 systems at year-end 2025 (52% CAGR over 2021-2025), with procedures growing at a 44% CAGR. FY2025 HIFU revenue was €33.1M ($37.4M, +39% YoY) and Q1 2026 total revenue hit a record $17.8M (+25% YoY) including $11.6M of HIFU (+78% YoY). Management has guided 2026 total revenue to $72-80M, with HIFU specifically at $50-54M. The company is reclassifying its legacy ESWL and Distribution segments as discontinued operations from Q2 2026 to focus capital on robotic HIFU, secured a €36M debt facility from the European Investment Bank in October 2025, and signed a letter of intent with Telix Pharmaceuticals in May 2026 to combine Focal One with PSMA PET imaging for image-guided focal therapy.

Short descriptiontext

EDAP TMS, now operating as FocalTherics (NASDAQ: FOCL), is a French medical device company that develops and sells the Focal One robotic HIFU system for non-invasive prostate tissue ablation, serving hospital urology departments and specialty urology clinics worldwide through direct enterprise sales, operating leases, and procedure-driven disposables.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersAustin, United States
HQ citystring
Austin
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
robotic HIFU systems, prostate tissue ablation, medical ultrasound devices, focal therapy equipment, urology medical devices
Industry3 codes
PRIMARYHLAHADAF
Surgical Robotics & Computer-Assisted Surgery Platforms
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHADAG
Surgical Navigation, Tracking & Intraoperative Guidance (Ortho/Neuro/ENT)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHABAG
Interventional Radiology & Image-Guided Therapy Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Surgical Appliance and Supplies Manufacturing339113
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Therapeutic Ultrasound Medical Devices
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1HIFU Capital Equipment Sales
TypeHardware Sales
Description

Sale of Focal One robotic HIFU systems to hospitals and clinics. The company sold 69% more Focal One systems year-over-year in 2025 (with 14 systems sold in Q4 alone, comprising 14 cash sales and one operating lease). Q1 2026 saw 11 capital sales.

biospace.com
2Procedures and Disposables
TypeUsage Based
Description

Recurring revenue from procedures performed using Focal One systems. Worldwide disposables revenue grew 43% year-over-year. 53% growth in U.S. Focal One procedures in Q1 2026.

biospace.com
3Operating Lease
TypeSubscription Recurring
Description

Focal One systems placed under operating lease arrangements, providing recurring revenue stream.

globenewswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Focal One
Description

Robotic HIFU system for non-invasive prostate tissue ablation using high-intensity focused ultrasound technology

focalone.com
+2 more records
Core offering1 text field

EDAP TMS (now operating as FocalTherics) designs, manufactures, and sells the Focal One robotic High-Intensity Focused Ultrasound (HIFU) platform for non-invasive prostate tissue ablation. The company sells capital equipment (Focal One systems) directly to hospitals and urology clinics, generates recurring revenue from procedure-related disposables, and places systems via operating leases.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 71% androgen deprivation therapy-free survival at 30 months
+6 more records
Product overview1 text field

EDAP TMS (now operating as FocalTherics) offers the Focal One® platform, a comprehensive robotic HIFU system for non-invasive prostate tissue ablation. The core Focal One® HIFU Robotic System integrates several key components: the Robotic Positioning System providing submillimetric precision with five degrees of freedom, the HIFUsion® open-platform fusion software for MRI and 3D biopsy mapping, the Dynamic Focusing Probe combining real-time ultrasound imaging with HIFU energy delivery, and an Integrated Workstation for OR compatibility. The company also offers the Focal One i as an enhanced version of the platform. The company is transitioning away from non-core ESWL (Extracorporeal Shock Wave Lithotripsy) and Distribution segments to focus exclusively on its high-growth robotic HIFU business.

Product and service3 records
1Focal One HIFU Robotic System
CategoryRobotic HIFU Capital Equipment
Description

Flagship robotic High-Intensity Focused Ultrasound (HIFU) system used by urologists and hospitals to non-invasively ablate prostate tissue while sparing healthy surrounding tissue, with submillimetric precision and real-time ultrasound imaging.

2Focal One i
CategoryRobotic HIFU Capital Equipment
Description

Advanced iteration of the Focal One robotic HIFU platform with enhanced capabilities for non-invasive ablation of prostate tissue controlled by urologists.

3Focal One Eye
CategoryRobotic HIFU Capital Equipment
Description

Focal One Eye system launched in the U.S. market in August 2025 for non-invasive prostate tissue ablation using HIFU technology.

Scale indicator19 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-14
Description

EDAP TMS entered into a non-binding letter of intent with Telix Pharmaceuticals to explore joint clinical research combining Focal One Robotic HIFU with Telix's PSMA PET imaging products for prostate cancer management. The collaboration aims to optimize treatment planning, deliver image-guided focal therapy, and monitor patient responses in both primary and salvage treatment settings following radiation therapy. The parties may explore clinician educational programs and clinical studies. No financial commitments have been made and there is no assurance that definitive agreements will result from this initial collaboration.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Profound Medical develops the TULSA-PRO system, an MRI-guided transurethral ultrasound ablation platform for prostate tissue — the closest direct competitor to Focal One in robotic, image-guided prostate ablation. Both target the same focal-therapy indication and similar urology customer base.

TypeDirect peer
Description

SonaCare Medical commercializes the Sonablate system, a high-intensity focused ultrasound (HIFU) platform for transrectal prostate tissue ablation. It competes head-to-head with Focal One in the same focal-therapy indication and overlapping urology customer base.

3HistoSonics
TypeEmerging player
Description

HistoSonics develops the Edison histotripsy platform, a non-invasive, non-thermal focused-ultrasound tissue destruction technology that overlaps with HIFU in mechanism and prostate indication. It is an emerging, venture-backed competitor entering the focal-therapy space that could pressure HIFU incumbents.

TypeBroad incumbent
Description

Insightec commercializes Exablate, a MR-guided focused ultrasound (MRgFUS) platform with multiple clinical applications including prostate and other oncology indications. It is a broader focused-ultrasound incumbent with overlapping technology roots but a wider indication portfolio than Focal One.

TypeBroad incumbent
Description

Boston Scientific is a large diversified medical-device company with a urology portfolio including Rezūm water-vapor thermal therapy for BPH and other prostate-treatment technologies. It competes indirectly by offering alternative minimally invasive urology treatments within the same hospital purchasing workflows.

TypeBroad incumbent
Description

AngioDynamics manufactures and sells a portfolio of minimally invasive and ablation devices used across multiple specialties, including interventional oncology. While it does not specialize in HIFU, it overlaps with FocalTherics in image-guided tissue ablation and hospital oncology customers.

TypeBroad incumbent
Description

Varian, a Siemens Healthineers company, is a global leader in radiation oncology (including prostate cancer) with CyberKnife and conventional linear accelerators. It represents the entrenched radical-treatment incumbent that focal therapies like Focal One are displacing or substituting for in select patients.

TypeBroad incumbent
Description

Elekta is a major provider of radiation therapy and radiosurgery systems used in prostate cancer treatment. It competes indirectly with Focal One by representing the standard-of-care radical treatment against which focal therapy is benchmarked.

TypeBroad incumbent
Description

Medtronic is a diversified medical-device leader with ablation, surgical, and urology-adjacent product lines. While not a focused HIFU competitor, it competes broadly in the same hospital capital-equipment purchasing cycles and minimally invasive procedure categories.

TypeRegional player
Description

HealthTronics provides urology-focused capital equipment, services, and lithotripsy solutions across North America. It is a regional urology services and devices player that intersects with FocalTherics in BPH and stone management devices and shares similar hospital-urology customers, though it does not directly compete in HIFU.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

EDAP TMS

Therapeutic Ultrasound Medical Devicesedap-tms.com

EDAP TMS, now operating as FocalTherics (NASDAQ: FOCL), is a French medical device company that develops and sells the Focal One robotic HIFU system for non-invasive prostate tissue ablation, serving hospital urology departments and specialty urology clinics worldwide through direct enterprise sales, operating leases, and procedure-driven disposables.

What EDAP TMS does

EDAP TMS S.A., now operating as FocalTherics (NASDAQ: FOCL, formerly EDAP), is a French medical device company that has pivoted from a diversified therapeutic ultrasound portfolio to a pure-play robotic focal therapy business. The company develops and commercializes the Focal One platform — a robotic High Intensity Focused Ultrasound (HIFU) system for non-invasive prostate tissue ablation. Focal One combines a five-degrees-of-freedom robotic positioning system with submillimetric precision, a Dynamic Focusing Probe that fuses real-time ultrasound imaging with HIFU energy delivery, and the proprietary HIFUsion open-platform software that performs elastic fusion of MRI and 3D biopsy maps for treatment planning. The platform is sold as the Focal One and Focal One i systems, with the Focal One Eye variant launched in the U.S. in August 2025. Headquartered in Lyon, France with a U.S. commercial office in Austin, Texas, the company holds regulatory clearances in the U.S., Europe, Canada, Korea, Russia, Brazil, and other markets, supported by 154 peer-reviewed publications and major clinical studies including HIFI, FARP, and HIFI-2.

The company generates revenue through direct enterprise capital sales of Focal One systems to hospital urology departments and specialty urology clinics, supplemented by an operating lease option and a recurring procedure-driven disposables stream. The installed base reached 87 systems at year-end 2025 (52% CAGR over 2021-2025), with procedures growing at a 44% CAGR. FY2025 HIFU revenue was €33.1M ($37.4M, +39% YoY) and Q1 2026 total revenue hit a record $17.8M (+25% YoY) including $11.6M of HIFU (+78% YoY). Management has guided 2026 total revenue to $72-80M, with HIFU specifically at $50-54M. The company is reclassifying its legacy ESWL and Distribution segments as discontinued operations from Q2 2026 to focus capital on robotic HIFU, secured a €36M debt facility from the European Investment Bank in October 2025, and signed a letter of intent with Telix Pharmaceuticals in May 2026 to combine Focal One with PSMA PET imaging for image-guided focal therapy.

EDAP TMS firmographics

Firmographics
Name
EDAP TMS
Legal name
EDAP TMS S.A.
Website
https://edap-tms.com
Company type
Public
Founded year
1979
Operating status
Operating
Headcount range
251–500 employees
Short description
EDAP TMS, now operating as FocalTherics (NASDAQ: FOCL), is a French medical device company that develops and sells the Focal One robotic HIFU system for non-invasive prostate tissue ablation, serving hospital urology departments and specialty urology clinics worldwide through direct enterprise sales, operating leases, and procedure-driven disposables.
Ownership category
akta.pro rank

EDAP TMS industry classification

Industry
Product category
Therapeutic Ultrasound Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHADAF
Surgical Robotics & Computer-Assisted Surgery Platforms
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHADAG
Surgical Navigation, Tracking & Intraoperative Guidance (Ortho/Neuro/ENT)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHABAG
Interventional Radiology & Image-Guided Therapy Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment

Keywords

  • Robotic HIFU systems
  • Prostate tissue ablation
  • Medical ultrasound devices
  • Focal therapy equipment
  • Urology medical devices

Where EDAP TMS is headquartered

Location

Headquarters

HQ city
Austin
HQ country
United States
HQ region
North America

Offices2 records

Markets served

EDAP TMS business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. HIFU Capital Equipment Sales: Sale of Focal One robotic HIFU systems to hospitals and clinics. The company sold 69% more Focal One systems year-over-year in 2025 (with 14 systems sold in Q4 alone, comprising 14 cash sales and one operating lease). Q1 2026 saw 11 capital sales.
  2. Procedures and Disposables: Recurring revenue from procedures performed using Focal One systems. Worldwide disposables revenue grew 43% year-over-year. 53% growth in U.S. Focal One procedures in Q1 2026.
  3. Operating Lease: Focal One systems placed under operating lease arrangements, providing recurring revenue stream.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

EDAP TMS product offering

Product offering

Core offering

EDAP TMS (now operating as FocalTherics) designs, manufactures, and sells the Focal One robotic High-Intensity Focused Ultrasound (HIFU) platform for non-invasive prostate tissue ablation. The company sells capital equipment (Focal One systems) directly to hospitals and urology clinics, generates recurring revenue from procedure-related disposables, and places systems via operating leases.

Product overview

EDAP TMS (now operating as FocalTherics) offers the Focal One® platform, a comprehensive robotic HIFU system for non-invasive prostate tissue ablation. The core Focal One® HIFU Robotic System integrates several key components: the Robotic Positioning System providing submillimetric precision with five degrees of freedom, the HIFUsion® open-platform fusion software for MRI and 3D biopsy mapping, the Dynamic Focusing Probe combining real-time ultrasound imaging with HIFU energy delivery, and an Integrated Workstation for OR compatibility. The company also offers the Focal One i as an enhanced version of the platform. The company is transitioning away from non-core ESWL (Extracorporeal Shock Wave Lithotripsy) and Distribution segments to focus exclusively on its high-growth robotic HIFU business.

Differentiator

Problem solved

Functional benefit

Brands

  • Focal One: Robotic HIFU system for non-invasive prostate tissue ablation using high-intensity focused ultrasound technology
  • Focal One i
  • HIFUsion

Products and services

  • Focal One HIFU Robotic System Flagship robotic High-Intensity Focused Ultrasound (HIFU) system used by urologists and hospitals to non-invasively ablate prostate tissue while sparing healthy surrounding tissue, with submillimetric precision and real-time ultrasound imaging.
  • Focal One i Advanced iteration of the Focal One robotic HIFU platform with enhanced capabilities for non-invasive ablation of prostate tissue controlled by urologists.
  • Focal One Eye Focal One Eye system launched in the U.S. market in August 2025 for non-invasive prostate tissue ablation using HIFU technology.

Quantifiable outcome

  • 71% androgen deprivation therapy-free survival at 30 months
  • +6 more outcomes

Companies that use EDAP TMS

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles2 records

EDAP TMS technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

EDAP TMS partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Telix PharmaceuticalscoreStrategic or Co-development Partner · 14 May 2026EDAP TMS entered into a non-binding letter of intent with Telix Pharmaceuticals to explore joint clinical research combining Focal One Robotic HIFU with Telix's PSMA PET imaging products for prostate cancer management. The collaboration aims to optimize treatment planning, deliver image-guided focal therapy, and monitor patient responses in both primary and salvage treatment settings following radiation therapy. The parties may explore clinician educational programs and clinical studies. No financial commitments have been made and there is no assurance that definitive agreements will result from this initial collaboration.

Scale indicators19 records

Recent moves8 records

Expansion highlights6 records

EDAP TMS competitors and assessment

Company assessment

Direct peers

  • Profound Medical Corp: Profound Medical develops the TULSA-PRO system, an MRI-guided transurethral ultrasound ablation platform for prostate tissue — the closest direct competitor to Focal One in robotic, image-guided prostate ablation. Both target the same focal-therapy indication and similar urology customer base.
  • SonaCare Medical: SonaCare Medical commercializes the Sonablate system, a high-intensity focused ultrasound (HIFU) platform for transrectal prostate tissue ablation. It competes head-to-head with Focal One in the same focal-therapy indication and overlapping urology customer base.

Emerging players

  • HistoSonics: HistoSonics develops the Edison histotripsy platform, a non-invasive, non-thermal focused-ultrasound tissue destruction technology that overlaps with HIFU in mechanism and prostate indication. It is an emerging, venture-backed competitor entering the focal-therapy space that could pressure HIFU incumbents.

Broad incumbents

  • Insightec: Insightec commercializes Exablate, a MR-guided focused ultrasound (MRgFUS) platform with multiple clinical applications including prostate and other oncology indications. It is a broader focused-ultrasound incumbent with overlapping technology roots but a wider indication portfolio than Focal One.
  • Boston Scientific: Boston Scientific is a large diversified medical-device company with a urology portfolio including Rezūm water-vapor thermal therapy for BPH and other prostate-treatment technologies. It competes indirectly by offering alternative minimally invasive urology treatments within the same hospital purchasing workflows.
  • AngioDynamics: AngioDynamics manufactures and sells a portfolio of minimally invasive and ablation devices used across multiple specialties, including interventional oncology. While it does not specialize in HIFU, it overlaps with FocalTherics in image-guided tissue ablation and hospital oncology customers.
  • Varian (Siemens Healthineers): Varian, a Siemens Healthineers company, is a global leader in radiation oncology (including prostate cancer) with CyberKnife and conventional linear accelerators. It represents the entrenched radical-treatment incumbent that focal therapies like Focal One are displacing or substituting for in select patients.
  • Elekta: Elekta is a major provider of radiation therapy and radiosurgery systems used in prostate cancer treatment. It competes indirectly with Focal One by representing the standard-of-care radical treatment against which focal therapy is benchmarked.
  • Medtronic: Medtronic is a diversified medical-device leader with ablation, surgical, and urology-adjacent product lines. While not a focused HIFU competitor, it competes broadly in the same hospital capital-equipment purchasing cycles and minimally invasive procedure categories.

Regional players

  • HealthTronics: HealthTronics provides urology-focused capital equipment, services, and lithotripsy solutions across North America. It is a regional urology services and devices player that intersects with FocalTherics in BPH and stone management devices and shares similar hospital-urology customers, though it does not directly compete in HIFU.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

EDAP TMS social profiles

Digital presence

EDAP TMS financial estimates

Financial estimate

Revenue estimate

Valuation estimate

EDAP TMS leadership team

Management profile

Number of profiles

Profiles4 records

EDAP TMS funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

EDAP TMS M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EDAP TMS

What does EDAP TMS do?

EDAP TMS (now operating as FocalTherics) designs, manufactures, and sells the Focal One robotic High-Intensity Focused Ultrasound (HIFU) platform for non-invasive prostate tissue ablation. The company sells capital equipment (Focal One systems) directly to hospitals and urology clinics, generates recurring revenue from procedure-related disposables, and places systems via operating leases.

Is EDAP TMS a public or private company?

EDAP TMS is a public company. It is classified as public and is currently operating.

When was EDAP TMS founded?

EDAP TMS was founded in 1979. It employs 251 to 500 people.

Where is EDAP TMS based?

EDAP TMS is headquartered in Austin, United States, in the North America region.

How does EDAP TMS make money?

Three revenue lines are on record. HIFU Capital Equipment Sales are the primary driver. The others are procedures and Disposables and operating Lease.

Who are EDAP TMS's main competitors?

Direct peers on record are Profound Medical Corp and SonaCare Medical. HistoSonics is listed as an emerging player. Broad incumbents are Insightec, Boston Scientific, AngioDynamics, Varian (Siemens Healthineers), Elekta and Medtronic. HealthTronics is listed as a regional player.

Does EDAP TMS have an API?

No public API is recorded for EDAP TMS.

What industry is EDAP TMS in?

EDAP TMS's product category is Therapeutic Ultrasound Medical Devices. Its primary akta.pro industry code is HLAHADAF, Surgical Robotics & Computer-Assisted Surgery Platforms, with a secondary code of HLAHADAG, Surgical Navigation, Tracking & Intraoperative Guidance (Ortho/Neuro/ENT). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaEDAP TMS S.A. (FOCL) Presents at 2026 UBS Global Healthcare Conference TranscriptFocalTherics CEO Ryan Rhodes presented at the 2026 UBS Global Healthcare Conference, stating the company's revenue grew from $16 million to $26 million through 2024. The company targets 38% year-over-year growth, reaching approximately $55 million in revenue this year.MarketScreenerCertain Warrants of EDAP TMS S.A. are subject to a Lock-Up Agreement Ending on 10-NOV-2026.EDAP TMS S.A. has agreed to a lock-up agreement ending on 10 November 2026, restricting issuance, sale, or disposal of securities and executive officers' trading of ADSs and ordinary shares. The agreement, subject to customary exceptions, requires prior written consent from underwriters TD Securities and Mizuho Securities USA.American Banking and Market NewsFocalTherics (NASDAQ:FOCL) Raised to Hold at Wall Street ZenWall Street Zen upgraded FocalTherics from sell to hold, while other analysts have mixed ratings. The company reported a loss of $0.10 per share, beating estimates, and insiders bought 116,000 shares in the last quarter.American Banking and Market NewsFocalTherics Q3 Earnings Call HighlightsFocalTherics reported Q3 2026 revenue of $9.8 million, up 26% year-over-year, from seven Focal One capital system sales. The company narrowed its 2026 revenue guidance to $50-52 million from $50-54 million, citing delayed hospital purchases. It expects procedure growth to remain consistent as the installed base expands.TradingViewEDAP TMS Q3 2026 Earnings Call Is LiveEDAP TMS's Q3 2026 earnings call is live, with executives discussing financial results and answering analyst questions. Management commentary on demand, margins, or capital spending may move markets.Business & FinancialFocalthericstm Reports Third Quarter 2026 Financial ResultsFocalTherics reported Q3 2026 results with total net sales of $9,828,000 and a net loss of $4,462,000. The company's HIFU division generated $5,053,000 in gross profit, while operating expenses totaled $12,829,000. Cash flow from operations was negative $10,687,000 for the nine months ended September 30, 2026.Stock TitanFocalTherics schedules 3 investor conference appearancesFocalTherics announced it will participate in three investor conferences, starting with the UBS Global Healthcare Conference on November 10, 2026. Management will also host 1x1 meetings at the Jefferies conference on November 18 and a fireside chat at the Piper Sandler conference on December 2.MarketBeatFocalTherics (FOCL) - What Are Investment Firms Saying About This Stock?FocalTherics received a consensus 'Hold' rating from five brokerages, with an average price objective of $7.75. The company reported a quarterly loss of $0.39 per share, missing the $0.20 consensus, and revenue of $13.20 million. Insiders bought 116,000 shares in the last 90 days, and institutional ownership stands at 62.74%.GlobeNewswireFocalTherics™ to Announce Third Quarter 2026 Financial Results on November 5, 2026FocalTherics will release its third-quarter 2026 financial results after market close on November 5, 2026, and will host a conference call and webcast with CEO Ryan Rhodes and CFO Ken Mobeck. The company, a robotic focal therapy developer, will provide dial-in and webcast details for the call.Stock TitanFocalTherics Sets Q3 2026 Earnings Date for Nov. 5FocalTherics will release its third-quarter 2026 financial results after market close on November 5, 2026. The company will host a conference call and webcast with CEO Ryan Rhodes and CFO Ken Mobeck at 4:30 p.m. ET. The results cover the quarter ended September 30, 2026.